Last reviewed · How we verify
Obturator block
Obturator block, developed by the University of Florida, is a marketed product with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Obturator block |
|---|---|
| Also known as | Ultrasound guided nerve block anesthetic, Mepivacaine, Pajunk SonoPlex needle |
| Sponsor | University of Florida |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- COMPARISON OF OBTURATOR NERVE BLOCK TECHNIQUES IN TURBT (NA)
- Local Infiltration Analgesia Versus Quadruple Nerve Blocks in Total Knee Arthroplasty. (NA)
- FRONT Block for Quality of Recovery After Total Hip Arthroplasty (NA)
- PENG Block vs Suprainguinal FICB vs Lumbar ESPB for Analgesia After Hip Surgery (NA)
- Femoral Rami Obturator Nerve Trunk (FRONT) Block in Intramedullary Nail Surgery . (NA)
- Infiltration or Nerve Blocks in Addition to Adductor Canal Block (NA)
- Peripheral Nerve Blocks for Above-the-knee Amputations (PHASE4)
- PENG vs PHPB for Hip Arthroplasty Analgesia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |